Bariatric Surgery and Remission of Metabolic Syndrome: A Meta-analysis of Randomised Controlled Trials and Prospective Studies

Basit Öğe Kaydı
dc.authoridMohamed, Mohamed Ibrahim/0009-0001-8618-1898
dc.authoridYakout, Abdelrahman/0009-0000-8605-9123
dc.authoridNassar, Moussa/0009-0001-1580-8091
dc.authoridOmayer, Abu/0009-0008-1327-5210
dc.contributor.authorDean, Yomna E.
dc.contributor.authorMohamed, Mohamed I.
dc.contributor.authorShokri, Abdulrahman
dc.contributor.authorNassar, Moussa
dc.contributor.authorOmayer, Abu
dc.contributor.authorShahid, Maryam
dc.contributor.authorSharif, Arsalan
dc.date.accessioned2025-05-29T02:58:03Z
dc.date.available2025-05-29T02:58:03Z
dc.date.issued2025
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractBackground Studies have discussed the efficacy of bariatric surgery (BS) in remission of individual components of metabolic syndrome (MS). We aimed to analyse the prevalence of MS following BS. Methods On October 5, 2023, we conducted a literature search on PubMed, Scopus, Web of Science, and Cochrane. RevManv5.4 was used for the analysis. Results MS patients who underwent BS had lower odds of MS within the first year post-BS (OR 0.14, 95%CI 0.12-0.17); patients who had a preoperative BMI < 50 showed a higher reduction in MS post-BS compared with patients who suffered from super obesity (OR 0.12 versus OR 0.17). Older patients (age > 42) had lower odds of MS post-BS compared with younger patients (OR 0.05 versus OR 0.17). There was not a difference in MS prevalence between 1 and 2 years postoperatively (OR 1.07, 95%CI 0.72-1.58). Asians reported the highest reduction in MS post-BS (OR 0.08). MS patients who received medical treatment had three times the odds of having MS compared with patients who underwent BS. Patients who had BS reported a decline in their anti-hypertensives and oral anti-diabetic drugs (OR 0.26, 95%CI 0.15-0.46, OR 0.11, 95%CI 0.07-0.16, respectively). There was not a significant difference in MS prevalence between patients who underwent RYGB and those who had SG (OR 2.16, 95%CI 0.74-6.26). Conclusions BS is superior to medical treatment in the remission of MS. Age, preoperative BMI, and country of origin affect the rates of MS remission. BS results in a sustainable resolution of MS across 1, 2, and 5 years post-surgery. A tailored approach is warranted to achieve the best outcomes.
dc.identifier.doi10.1007/s11695-025-07750-7
dc.identifier.endpage1349
dc.identifier.issn0960-8923
dc.identifier.issn1708-0428
dc.identifier.issue4
dc.identifier.pmid40000567
dc.identifier.scopus2-s2.0-85218909069
dc.identifier.scopusqualityQ1
dc.identifier.startpage1337
dc.identifier.urihttps://doi.org/10.1007/s11695-025-07750-7
dc.identifier.urihttps://hdl.handle.net/20.500.12428/30258
dc.identifier.volume35
dc.identifier.wosWOS:001431300600001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSpringer
dc.relation.ispartofObesity Surgery
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250529
dc.subjectMetabolic syndrome
dc.subjectBariatric surgery
dc.titleBariatric Surgery and Remission of Metabolic Syndrome: A Meta-analysis of Randomised Controlled Trials and Prospective Studies
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu